Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results
July 22, 2020 16:05 ET
|
Entera Bio Ltd.
‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒ ‒ Oral PTH Described by Clinicians as Potential Game-Changer...
Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis
July 07, 2020 08:30 ET
|
Entera Bio Ltd.
‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒ ‒ Company Continues to Expect Completion of...
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
May 21, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six...
Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020
May 07, 2020 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, May 07, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report interim...
ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019
March 26, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒‒ Financing Completed in...
ENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020
March 16, 2020 16:15 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report...
Entera Bio Announces the Completion of $14.3 million Private Placement
December 18, 2019 16:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased...
Entera Announces Closing of Private Placement
December 11, 2019 17:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed...
Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update
November 21, 2019 07:00 ET
|
Entera Bio Ltd.
Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism...
Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer
November 21, 2019 07:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as...